Vincent speaks with Raul and Kostya about the development of novel oral polio vaccine from the Sabin type 2 strain, its deployment in over 600 million children, and whether it can lead to eradication of poliomyelitis.
Vincent speaks with Kostya Chumakov about his career: raised by two virology parents in Moscow, trained in virology by Vadim Agol, then moving to the US FDA where he developed a molecular test for measuring production consistency of oral poliovirus vaccine.
TWiV discusses genetic evidence of susceptible wildlife in SARS-CoV-2 positive samples at the Huanan Wholesale Seafood Market, polio cases in African linked to a new polio vaccine that was designed to not cause the disease, and structural conservation of hepatitis B virus capsid proteins over millions of years despite a shift from a naked to an enveloped capsid.
TWiV reviews the genetic characterization of a new strain of type 2 oral polio vaccine and its implications for eradication, and how a polymorphism in humans comprising a single amino acid change in an antibody molecule regulates vaccine elicitation of broadly neutralizing antibodies against influenza virus HA.
The TWiVstars reveal the diversity of herpes simplex virus type 2 in a neonatal population, and parallel adaptation of rabbits in three countries to myxoma virus.
Brianne and Vincent tackle two studies that utilize infectious viruses to examine zoonotic potential of Bombali virus, a new ebolavirus from an insectivorous species in Sierra Leone, and a human mumps-like virus from an African flying fox in DRC.
The TWiVologists discuss the finding of a second transmissible cancer in Tasmanian devils, and development of new poliovirus strains for the production of inactivated vaccine in the post-eradication era.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Rich Condit, Ph.D.
Dickson D.
Despommier, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.